Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs Basal Health

AM Rx
Graded #490

Higher grade

vs+2.1999999999999957
Basal Health
Graded #494

Lower grade

The verdict

AM Rx takes it — 49.9/100 to 47.7/100.

AM Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AM Rx (getamrx.com) is a telehealth platform operated by FitRX, LLC (also operates Zealthy and FitRx).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAM Rx +6
51
45
Dose & formulationAM Rx +25
65
40
Clinical oversightBasal Health +7
41
48
Labs & monitoringBasal Health +1
49
50
FulfillmentEven
58
58
Contract termsBasal Health +35
20
55
AM Rx · left barBasal Health · right bar

The numbers

MetricAM RxBasal Health
WeighScore49.9/10047.7/100
GradeCC
Scorecard rank#490#494
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
AM Rx

Graded #490 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Basal Health

Graded #494 · C

Strengths

  • Stated nationwide coverage (50 states + DC)
  • Metabolic-framework positioning rather than single-product
  • Clinician-supervised dosing rather than a fixed protocol
  • Adaptive monitoring approach

Where it loses points

  • No pricing shown publicly — you must complete intake to see cost
  • Compounding pharmacy partner not named
  • GLP-1 molecules not specified (semaglutide vs tirzepatide vs oral)
  • No LegitScript badge visible on the homepage
  • No FDA compounded-medication disclaimer on the pages reviewed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard